|
![]() |
|
|
Sulfamethizole
drug data and news
Sulfamethizole drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Sulfamethizole | ||
| Brand Names/Synonyms | Ayerlucil; CCRIS 756; CHEMBANK799; Famet; HSDB 4379; Lucosil; Methazol; Microsul; Proklar; RP 2145; Renasul; Rufol; S5632; SULFAMETHIAZOLE; Salimol; Solfametizolo [Dcit]; Sulamethizole; Sulfa Gram; Sulfamethazole; Sulfamethizol; Sulfamethizole; Sulfamethizole [Usan:Inn:Jan]; Sulfamethizolum [Inn-Latin]; Sulfamethylthiadiazole; Sulfametizol [Inn-Spanish]; Sulfapyelon; Sulfstat; Sulfurine; Sulphamethizole; Sulphamethyltiadiazole; Tetracid; Thidicur; Thiosulfil; Thiosulfil Forte; Ultrasul; Urocydal; Urodiaton; Urolucosil; Urosulfin; Uroz; VK 53 | ||
| Indication | For the treatment of urinary tract infection | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Sulfamethizole is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus. | ||
| Mechanism Of Action | Sulfamethizole is a competitive inhibitor of bacterial para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid. | ||
| Sulfamethizole News (When available) |
| ||
| Dosage Forms | TABLET | ||
| Drug_Category | Anti-Infectives; ATC:B05CA04; ATC:D06BA04; ATC:J01EB02; ATC:S01AB01 | ||
| Absorption | Rapidly absorbed. | ||
| Interactions |
Interactions for Sulfamethizole: Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin). | ||
| Toxicity | Not Available | ||
| Organisms Affected | Not Available | ||
| Chemical IUPAC Name | 4-amino-N-(5-methyl-1,3,4-thiadiazol-2-yl)-benzenesulfonamide | ||
| Chemical Formula | C9H10N4O2S2 | ||
| Molecular Weight | 270.333 g/mol | ||
| Smiles String | CC1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N | ||
| Melting Point | 208 °C | ||
| Water Solubility | 1050 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 2.968 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic. | ||
| Half Life | 3-8 hours | ||
| Protein Binding [%] | 98-99% | ||
| RxList Link | Not Available>RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.drugs.com/cons/Sulfamethizole.html | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00684 | ||
| CAS Registry Number | 144-82-1 | ||
| KEGG Compound ID | C08050 | ||
| PubChem ID | SID:10250 | ||
| PharmGKB ID | PA451543 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |